The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results – long-lasting with high survival rates – researchers report. First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, presented the updated data at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.Continue reading

New research suggests melanoma skin cancer may be controllable by starving its cells. Building on previous success with prostate cancer cells, scientists in Australia showed they could stop cell growth by blocking the pumps that melanoma cells use to acquire an essential cell nutrient.Continue reading